Vimarsana
Biggest News Aggregation in the World

Page 12 - Biocon Biologic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biocon Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biocon Biologic Today - Breaking & Trending Today

Ireland regulator reports manufacturing deficiency at Biocon's Bengaluru plant - Vimarsana News

Ireland regulator reports manufacturing deficiency at Biocon's Bengaluru plant

Biotechnology major Biocon Biologics on Tuesday said Ireland's health regulator has reported some deficiencies in the manufacturing process at the company's plant in Bengaluru. The Health Products Regulatory Authority (HPRA), Ireland, conducted a GMP (Good Manufacturing Practice) inspection of one of Biocon Biologics' new monoclonal antibody drug substance manufacturing

Biocon Biologics bags Rs 689 crore contract for Insugen from Malaysian Govt - Vimarsana News

Biocon Biologics bags Rs 689 crore contract for Insugen from Malaysian Govt

The rh-Insulin formulations, Insugen-R, Insugen-N and lnsugen-30/70, are manufactured at Biocon Sdn. Bhd.'s Johor facility.

'Dramatic expansion': Goodwin's London turnover spikes 63% amid lateral bonanza - Vimarsana News

'Dramatic expansion': Goodwin's London turnover spikes 63% amid lateral bonanza

The London office of Goodwin has seen revenue soar 63% in 2021/22 amid a surge in lateral hires over the year, the firm’s latest financial results reveal.

Biocon Biologics To Acquire Viatris' Biosimilars Assets For Up To $3.34 Billion - Vimarsana News

Biocon Biologics To Acquire Viatris' Biosimilars Assets For Up To $3.34 Billion

Biocon-Viatris deal: Viatris will receive a $2 billion in cash on closing of the deal and up to $335 million as additional payments in 2024. Viatris will designate Rajiv Malik, its president, to serve on Biocon Biologics’ board.

Biocon Biologics' IPO Within Next 2 Years, Says Kiran Mazumdar-Shaw - Vimarsana News

Biocon Biologics' IPO Within Next 2 Years, Says Kiran Mazumdar-Shaw

Biocon Biologics, a subsidiary of Biocon, will file for an initial public offer (IPO) within the next two years, Kiran Mazumdar-Shaw said on Monday.

Source: ndtv.com